ALDEYRA THERAPEUTICS, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $25.7M | $48.2M | $29.5M | $47.3M | $44.9M | $24.7M | $44.4M |
| SG&A Expense | — | $9.6M | $11.9M | $13.3M | $15.4M | $11.3M | $10.0M | $12.2M |
| Operating Income | — | $-35.3M | $-60.1M | $-42.8M | $-62.7M | $-56.2M | $-36.4M | $-63.1M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | $2.1M | $1.7M | $1.7M | $1.9M | $603.8K |
| Pretax Income | — | — | — | — | — | $-57.8M | $-38.0M | $-62.1M |
| Income Tax Expense | — | $0 | $1.0K | $0 | $0 | $0 | $-479.3K | $-1.3M |
| Net Income | — | $-33.8M | $-55.9M | $-37.5M | $-62.0M | $-57.8M | $-37.6M | $-60.8M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-0.56 | $-0.94 | $-0.64 | $-1.06 | $-1.07 | $-1.11 | $-2.24 |
| EPS (Diluted) | — | $-0.56 | $-0.94 | $-0.64 | $-1.06 | $-1.07 | $-1.11 | $-2.24 |
| Shares Outstanding (Basic) | 60.2M | 60.1M | 59.5M | 58.9M | 58.4M | 54.0M | 38.7M | 28.7M |
| Shares Outstanding (Diluted) | 60.2M | 60.1M | 59.5M | 58.9M | 58.4M | 54.0M | 38.7M | 28.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |